痛风患者血清P2X_7R水平的检测及其与炎症因子的相关性研究

Serum P2X_7 receptor levels and its correlation with inflammatory factors in gout patients

目的通过检测痛风性关节炎患者血清中嘌呤能受体(P2X_7R)及痛风相关炎症因子的水平,并分析P2X_7R与痛风相关炎症因子的相关性,探讨P2X_7 R在痛风发病中的作用。方法采用ELISA法检测20例痛风初次发作患者(痛风组,包括急性发作期和完全缓解期)、20例高尿酸血症患者(高尿酸血症组)及20例健康志愿者(健康对照组)血清中P2X_7R、IL-1β、TNF-α、IL-6、IL-8及IL-18水平,比较痛风组患者急性发作期和完全缓解期各指标间的差异,以及痛风组患者急性发作期和完全缓解期与其他两组问的差异;分析各组P2X_7 R水平与血沉、C反应蛋白、IL-1β、TNF-o、IL-6、IL-8及IL-18水平的相关性。结果痛风组患者急性发作期的P2X_7 R、IL-1β、TNF-α、IL-6、IL-8及IL-18水平均显著高于完全缓解期、高尿酸血症组及健康对照组,差异均有统计学意义(均P<0.05);而痛风组患者完全缓解期、高尿酸血症组及健康对照组的P2X_7 R、IL-1β、TNF-α、IL-6、IL-8及IL-18水平组间比较均无明显统计学差异(均P>0.05)。P2X_7 R表达与血沉、C反应蛋白、IL-1β及IL-18均呈正相关(均P<0.05),而与TNF-α、IL-6及IL-8无明显相关(P>0.05)。结论痛风患者急性发作期血清中的P2X_7 R表达水平升高且与血沉、C反应蛋白、IL-1β及IL-18炎症指标密切相关,推测P2X_7 R可能是痛风急性发作的一个关键因素,并可能成为预防痛风的急性发作的新靶点。

Objective To determine serum levels of P2X7 receptor and inflammatory factors and to analyze their correla-tion in gout patients. Methods Serum levels of P2X7 receptor, IL- 1β, TNF- α, IL- 6, IL- 8 and IL- 18 were detected by ELISA method in 20 patents with gout, 20 patents with hyperuricemia and 20 healthy subjects, the correlations of serum P2X7 receptor with inflammatory factors were analyzed. Results P2X7 receptor, IL- 1β, TNF- α, IL- 6, IL- 8 and IL- 18 levels in gout patients of acute attack stage were significantly higher than those in complete remission period （〈0.05）, and also higher than those in hyperuricemia group and healthy control group（P〈0.05）. There were no significant differences in P2X7 receptor, IL- 1β, TNF- α, IL- 6, IL- 8 and IL- 18 among patients with complete remission period, hyperuricemia and healthy controls （P〉0.05）.The level of serum P2X7 receptor was positively correlated with ESR, CRP, IL- 1βand IL- 18 （P〈0.05）, but not correlated with TNF- α, IL- 6 and IL- 8 （P〉0.05）. Conclusion The levels of P2X7 receptor in gout patients of acute attack stage are elevated, and closely correlated with inflammatory factors, indicating that P2X7 receptor may be a key factor in acute attack stage of gout, and may become a new target for prevention of acute attack in gout patients.